Background: Liver cancer is positioned third with regard to mortality related to cancer and is the sixth most frequently occuring cancer which is diagnosed worldwide. HCC being the predominant type has a dismal 8.37% survival rate of 5-year because of limited effective treatment options and high metastatic potential. The current treatment strategies which include surgical resection, liver ablation and transplantation are challenged by significant limitations and complications. HCC progression is closely linked to the Tumor-Suppressor Genes (TSGs) inactivation through mutations and abnormal promoter methylation, leading to genomic instability and uncontrolled cell proliferation. Epigenetic modifications, particularly DNA methylation, are crucial in the onset and progression of HCC. Phytochemicals, natural bioactive compounds from plants having anti-angiogenic, antioxidant and anti-inflammatory functions shown potential in regulating HCC metastasis. They target key molecular markers involved in cancer proliferation, migration and invasion, offering a promising therapeutic approach. Recent Findings: Epigenetic modifications such as DNA hypermethylation significantly contribute the progression of HCC by silencing critical TSGs involved in DNA repair, apoptosis and angiogenesis. Prominent hypermethylated TSGs include p73, ZNF382 and RASSF1A. Viral infections, particularly HBV and HCV, exacerbate the epigenetic disruptions, driving oncogenesis through pathways like PI3K/AKT, Wnt/β-catenin and YAP-Hippo signalling. Recent studies highlight the efficacy of phytochemicals in reversing these epigenetic alterations. For example, resveratrol targets the PI3K/AKT/mTOR pathway and enhances apoptosis by regulating antioxidant enzymes. Similarly, Sulforaphane inhibits angiogenesis and suppresses epithelial-mesenchymal transition (EMT), therby reducing tumor invasion and metastasis. Despite promisisng in vitro and in vivo results, challenges such as low bioavailability and the need for clinical validation persists. Conclusion: Phytochemicals hold significant promise as epigenetic modulators in HCC management, offering a complementary approach to existing therapies with potentially fewer side effects. Future reserach should focus on enhancing their bioavailability, comprehending their in vivo processes and carrying out clinical trials to confirm their effectiveness.